Market closed

ATAI Life Sciences/$ATAI

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Ticker

$ATAI

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Berlin, Germany

Employees

Website

www.atai.life

ATAI Metrics

BasicAdvanced

$238M

-

-$0.80

0.78 -

Price and volume

Market cap

$238M

Beta

0.78

52-week high

$2.85

52-week low

$1.03

Average daily volume

1.6M

Financial strength

Current ratio

5.807

Quick ratio

4.374

Long term debt to equity

14.451

Total debt to equity

16.271

Interest coverage (TTM)

-20.88%

Management effectiveness

Return on assets (TTM)

-25.70%

Return on equity (TTM)

-62.77%

Valuation

Price to revenue (TTM)

695.056

Price to book

1.64

Price to tangible book (TTM)

1.64

Price to free cash flow (TTM)

-2.87

Growth

Revenue change (TTM)

-0.90%

Earnings per share change (TTM)

84.55%

3-year revenue growth (CAGR)

-74.58%

3-year earnings per share growth (CAGR)

-15.52%

What the Analysts think about ATAI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.

ATAI Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ATAI Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ATAI News

AllArticlesVideos

atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline

Proactive Investors·5 days ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

GlobeNewsWire·5 days ago

atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts

Proactive Investors·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ATAI

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ATAI Life Sciences stock?

ATAI Life Sciences (ATAI) has a market cap of $238M as of January 15, 2025.

What is the P/E ratio for ATAI Life Sciences stock?

The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of January 15, 2025.

Does ATAI Life Sciences stock pay dividends?

No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next ATAI Life Sciences dividend payment date?

ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.

What is the beta indicator for ATAI Life Sciences?

ATAI Life Sciences (ATAI) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.